GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Flerie AB (OSTO:FLERIE) » Definitions » Short-Term Debt

Flerie AB (OSTO:FLERIE) Short-Term Debt : kr0.0 Mil (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Flerie AB Short-Term Debt?

Flerie AB's Short-Term Debt for the quarter that ended in Sep. 2024 was kr0.0 Mil.


Flerie AB Short-Term Debt Historical Data

The historical data trend for Flerie AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flerie AB Short-Term Debt Chart

Flerie AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Flerie AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Flerie AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Flerie AB Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Flerie AB's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Flerie AB Business Description

Traded in Other Exchanges
Address
Skeppsbron 16, Stockholm, SWE, 111 30
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations.

Flerie AB Headlines

No Headlines